Cargando…
External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
BACKGROUND: Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC). AIM: To independently evaluate the predictive performan...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245238/ https://www.ncbi.nlm.nih.gov/pubmed/34258254 http://dx.doi.org/10.1155/2021/9928065 |
_version_ | 1783716075036213248 |
---|---|
author | Gazda, Jakub Janicko, Martin Drazilova, Sylvia Grgurevic, Ivica Kanizaj, Tajana Filipec Koller, Tomas Bodorovska, Beatrica Mijic, Maja Mikolasevic, Ivana Stromar, Ivana Knezevic Kucinsky, Branislav Gazda, Matej Jarcuska, Peter |
author_facet | Gazda, Jakub Janicko, Martin Drazilova, Sylvia Grgurevic, Ivica Kanizaj, Tajana Filipec Koller, Tomas Bodorovska, Beatrica Mijic, Maja Mikolasevic, Ivana Stromar, Ivana Knezevic Kucinsky, Branislav Gazda, Matej Jarcuska, Peter |
author_sort | Gazda, Jakub |
collection | PubMed |
description | BACKGROUND: Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC). AIM: To independently evaluate the predictive performance of the URS model. METHODS: We used a cohort of Slovak and Croatian treatment-naïve PBC patients to quantify the discrimination ability using the area under receiver operating characteristic curve (AUROC) and its 95% confidence interval (CI). Furthermore, we evaluated the calibration using calibration belts. The primary outcome was treatment response after 12 months of UDCA therapy defined as values of alkaline phosphatase ≤1.67 × upper limit of normal. RESULTS: One hundred and ninety-four patients were included. Median pretreatment age was 56 years (interquartile range 49–62). Treatment response was achieved in 79.38% of patients. AUROC of the URS was 0.81 (95% CI 0.73–0.88) and the calibration belt revealed that response rates were correctly estimated by predicted probabilities. CONCLUSION: Our results confirm that the URS can be used in treatment-naïve PBC patients for estimating the treatment response probability after 12 months of UDCA therapy. |
format | Online Article Text |
id | pubmed-8245238 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-82452382021-07-12 External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis Gazda, Jakub Janicko, Martin Drazilova, Sylvia Grgurevic, Ivica Kanizaj, Tajana Filipec Koller, Tomas Bodorovska, Beatrica Mijic, Maja Mikolasevic, Ivana Stromar, Ivana Knezevic Kucinsky, Branislav Gazda, Matej Jarcuska, Peter Can J Gastroenterol Hepatol Research Article BACKGROUND: Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC). AIM: To independently evaluate the predictive performance of the URS model. METHODS: We used a cohort of Slovak and Croatian treatment-naïve PBC patients to quantify the discrimination ability using the area under receiver operating characteristic curve (AUROC) and its 95% confidence interval (CI). Furthermore, we evaluated the calibration using calibration belts. The primary outcome was treatment response after 12 months of UDCA therapy defined as values of alkaline phosphatase ≤1.67 × upper limit of normal. RESULTS: One hundred and ninety-four patients were included. Median pretreatment age was 56 years (interquartile range 49–62). Treatment response was achieved in 79.38% of patients. AUROC of the URS was 0.81 (95% CI 0.73–0.88) and the calibration belt revealed that response rates were correctly estimated by predicted probabilities. CONCLUSION: Our results confirm that the URS can be used in treatment-naïve PBC patients for estimating the treatment response probability after 12 months of UDCA therapy. Hindawi 2021-06-22 /pmc/articles/PMC8245238/ /pubmed/34258254 http://dx.doi.org/10.1155/2021/9928065 Text en Copyright © 2021 Jakub Gazda et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Gazda, Jakub Janicko, Martin Drazilova, Sylvia Grgurevic, Ivica Kanizaj, Tajana Filipec Koller, Tomas Bodorovska, Beatrica Mijic, Maja Mikolasevic, Ivana Stromar, Ivana Knezevic Kucinsky, Branislav Gazda, Matej Jarcuska, Peter External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis |
title | External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis |
title_full | External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis |
title_fullStr | External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis |
title_full_unstemmed | External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis |
title_short | External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis |
title_sort | external validation of udca response score in slovak and croatian patients with primary biliary cholangitis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245238/ https://www.ncbi.nlm.nih.gov/pubmed/34258254 http://dx.doi.org/10.1155/2021/9928065 |
work_keys_str_mv | AT gazdajakub externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT janickomartin externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT drazilovasylvia externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT grgurevicivica externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT kanizajtajanafilipec externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT kollertomas externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT bodorovskabeatrica externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT mijicmaja externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT mikolasevicivana externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT stromarivanaknezevic externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT kucinskybranislav externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT gazdamatej externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis AT jarcuskapeter externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis |